Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PeRinatal Outcomes with Active vs Expectant Management in PROM at Term
2024-517504-11-00Phase 3Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Jan 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dinoprostone, misoprostol, oxytocin and mifepristone in Rupture of amniotic membranes (PROM) (2 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Need for neonatal ventilatory support at delivery. Planned start Jan 2025; status: authorised.
02
Drugs
dinoprostonemisoprostoloxytocinmifepristone
03
Conditions
Rupture of amniotic membranes (PROM)
Beyond the preview
Go deeper on 2024-517504-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517504-11-00.